2/4
10:36 pm
nrix
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed [Yahoo! Finance]
Medium
Report
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share Shelf - What's Changed [Yahoo! Finance]
2/2
10:09 pm
nrix
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory [Yahoo! Finance]
2/2
09:40 am
nrix
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts [Yahoo! Finance]
Low
Report
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts [Yahoo! Finance]
1/29
11:48 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $30.00. They now have an "outperform" rating on the stock.
1/29
10:04 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) was given a new $35.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) was given a new $35.00 price target on by analysts at Stifel Nicolaus.
1/29
08:43 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/29
08:27 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
1/29
08:03 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
1/29
08:03 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/29
07:03 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/28
04:01 pm
nrix
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
Low
Report
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
1/25
12:33 pm
nrix
Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Nurix Therapeutics (NRIX) Valuation After Recent Share Price Volatility [Yahoo! Finance]
1/16
07:16 am
nrix
Nurix Therapeutics: Why This Company Could Double In Value? [Seeking Alpha]
Medium
Report
Nurix Therapeutics: Why This Company Could Double In Value? [Seeking Alpha]
1/12
07:20 am
nrix
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases [Yahoo! Finance]
1/12
07:00 am
nrix
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Medium
Report
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
1/8
07:09 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) was given a new $36.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) was given a new $36.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
1/5
07:00 am
nrix
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/21
10:00 pm
nrix
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]
Medium
Report
Does Strong Early Waldenström Data Redraw The Bull Case For Nurix Therapeutics' Degrader Platform (NRIX)? [Yahoo! Finance]
12/21
10:19 am
nrix
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT [Yahoo! Finance]
Medium
Report
Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT [Yahoo! Finance]
12/21
07:42 am
nrix
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge [Yahoo! Finance]
Medium
Report
Nurix Therapeutics (NRIX): Revisiting Valuation After a 120% Three-Month Share Price Surge [Yahoo! Finance]
12/16
10:17 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an "overweight" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an "overweight" rating on the stock.
12/10
09:42 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an "outperform" rating on the stock.
12/10
07:21 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/9
08:06 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at BTIG Research.
12/8
08:07 am
nrix
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Nurix Therapeutics (NASDAQ:NRIX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.